The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

Provided herein are chimeric antigen receptors (CARs) comprising a glucuronoxylomannan receptor antigen-binding domain. Further provided herein are immune cells expressing the GXMR-CARs as well as methods of their use in the treatment of cryptococcosis.

Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

The present disclosure is directed to antibodies binding to Aspergillus allergens and methods for use thereof.

The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing pharmaceutical compositions comprising such polypeptide fragments, pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of individual subjects.

This invention describes vaccine compositions and their methods of use utilizing inactivated fbp1Δ deletion mutant fungal cells.

The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of immunoprivileged tissue. It is described herein that an immunogenic composition which induces production of memory CD4 T cells allows for the access of a therapeutic antibody to the immunoprivileged tissue.

A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1.fwdarw.4)-[GlcNH—R].sub.n-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

The invention relates to recombinant yeasts of the Kluyveromyces lactis species for the production of a humoral immune response against defined antigens, to the production of said yeasts, and to the use thereof for protective vaccination against pathogens and malignant cells containing said antigens.

Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).